- Home
- AEXA vs STTK Comparison
AEXA vs STTK Comparison
Compare AEXA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEXA | STTK |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.3M | 652.4M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEXA | STTK |
|---|---|---|
| Price | $10.90 | $5.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.22 |
| AVG Volume (30 Days) | 76.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.49 | $1.70 |
| 52 Week High | $11.99 | $8.33 |
Technical Indicators
Market Signals| Indicator | AEXA | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 23.76 | 35.85 |
| Support Level | $10.70 | $3.55 |
| Resistance Level | $11.78 | $7.83 |
| Average True Range (ATR) | 0.17 | 0.46 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 22.83 | 5.65 |
Price Performance
Historical ComparisonAbout AEXA American Exceptionalism Acquisition Corp. A
American Exceptionalism Acquisition Corp A is a blank check company.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.